Zai Lab Limited

Hello, ladies and gentlemen. Thank you for standing by and welcome to Xylep's second quarter 2022 financial results conference call. At this time, all participants are in listen-only mode. Later, we will conduct a question and answer session and instructions will follow at that time. As a reminder, today's call is being recorded. It's now my pleasure to turn the floor over to Billy Cho, Chief Financial Officer of Xylep.

We'll make introductory comments. Thank you, Operator.

Good morning, good evening, and welcome, everyone. XyLab recently issued a press release providing the details of the company's financial results for the second quarter of 2022, as well as product highlights and corporate updates. The press release is available in the Investment Relations section of the company's website at ir.xylaboratory.com. Today's call will be led by Dr. Samantha Dew, XyLab's founder, chairperson, and chief executive officer. She'll be joined by Josh Smiley. Chief Operating Officer, who many of you know, and officially started this month and will discuss his priorities and focus areas for the company. Dr. Alan Sandler, President and Head of Global Development Oncology, who will discuss advances with our oncology product candidates. And Dr. Harold Reinhart, President and Head of Global Development Neuroscience, Autoimmune, and Infectious Diseases, who will speak about the progress we have made in those three therapeutic areas. And I will discuss the performance of our market products and conclude with comments on our financial results. Additional executives will be on to answer questions during the Q&A portion of the call. As a reminder, during today's call, Zyla will be making certain forward-looking statements within the meaning of the private securities litigation reform act of 1995, including our business plans and objectives and timing and success of our clinical trials, our sales and revenue forecast for the product and product candidates, regulatory applications, and commercial launches. Such forward-looking statements are not guarantees of future performance. and therefore should not put undue reliance upon them. These statements are subject to numerous risks and uncertainties. Actual results could differ materially from what we expect due to a variety of factors, including those discussed in our SEC filings. At this time, it is my pleasure to turn the call over to Xilab's founder, chairperson, and chief executive officer, Dr. Samantha Dew.